{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000002","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.456982+00:00","generated_at":"2026-06-06T15:52:38.462076+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial","bullets":["Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.","Co-led by 5AM Ventures and another life science investor; includes Ally Bridge, Sphera, Altium, Driehaus.","Net proceeds expected to fund operations into early 2026, including nimacimab Phase 2 obesity trial starting mid-2024.","Phase 2a SBI-100 OE trial for glaucoma currently enrolling; interim data expected Q1 2024, topline Q2 2024.","Directors and officers subject to 90-day lock-up; registration rights agreement filed within 60 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000002","json":"https://secwatch.observer/filing/0001516551-24-000002.json","markdown":"https://secwatch.observer/filing/0001516551-24-000002.md","text":"https://secwatch.observer/filing/0001516551-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000002/0001516551-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000002/skye-20240129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:52:38.462076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f29e2d8bd8f72a33fb8be7a5c400919f505177ce","claim":"Skye Bioscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $50,249,991 (effective 2024-01-29).","evidence_excerpt":"On January 29, 2024, Skye Bioscience, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing (i) an aggregate of 11,822,124 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), at a price of $2.305 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Closing Securities”) to purchase up to 9,978,739 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a price of $2.3049 per Pre-Funded Warrant (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000002/0001516551-24-000002-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"$50,249,991"},{"label":"Effective","value":"2024-01-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}